Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling.

Biochemical and biophysical research communications - 12 Dec 2014

Watanuki Zenta, Kosai Hitomi, Osanai Nanae, Ogama Naoko, Mochizuki Mai, Tamai Keiichi, Yamaguchi Kazunori, Satoh Kennichi, Fukuhara Tatsuro, Maemondo Makoto, Ichinose Masakazu, Nukiwa Toshihiro, Tanaka Nobuyuki

Abstract excerpt

EGFR is an important therapeutic target for non-small cell lung cancers (NSCLCs). Tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, are effective in cases with EGFR-activating mutations. However, most such cases become resistant through a secondary EGFR mutation, T790M. While the second-generation TKI afatinib has a higher affinity for double-mutant EGFRs, better efficacy is needed. Combining...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apoptosis Regulatory Proteins

Share to Bcl-2-Like Protein 11

Share to Cetuximab

Share to K562 Cells

Share to Quinazolines

Share to rab GTP-Binding Proteins

Source

Identifiers

PMID: 25446083
DOI: 10.1016/j.bbrc.2014.11.003

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling.PMID 25446083Read ↗

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.Semantic proximity Read ↗

Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.Semantic proximity Read ↗

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.Semantic proximity Read ↗

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.Semantic proximity Read ↗

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.Semantic proximity Read ↗

Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.Semantic proximity Read ↗

Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.Semantic proximity Read ↗

Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.Semantic proximity Read ↗

Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.Semantic proximity Read ↗

Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation.Semantic proximity Read ↗

Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.